vimarsana.com
Home
Live Updates
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics : vimarsana.com
CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics
CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to... | June 5, 2023
Related Keywords
Russia ,
Phoenix ,
Arizona ,
United States ,
Ukraine ,
Briang Atwood ,
Daniel Corey ,
Chris Ehrlich ,
Nasdaq ,
Cero Therapeutics Holdings Inc ,
Phoenix Biotech Acquisition Corp ,
Goodwin Procter ,
Merger Sub Inc ,
Company Capital ,
Cero Therapeutics Inc ,
Exchange Commission ,
J Vb Financial Group ,
Technology Officer ,
Ellenoff Grossman Schole ,
Phoenix Biotech Acquisition ,
Therapeutics Holdings ,
Nasdaq Capital Market ,
Chief Executive Officer ,
Chief Financial Officer ,
Chief Operating Officer ,
Chief Technology ,
Current Report ,
Ellenoff Grossman ,
Company Capital Markets ,
Financial Group ,
Biotech Acquisition ,
Business Combination ,
Registration Statement ,
Business Combination Agreement ,
Merger Sub ,
Quarterly Report ,
Phoenix Biotech Acquisition Corp Stock Exchange ,
News ,
Information ,
Press Release ,
Hero ,
Us ,
N ,
Nnovative ,
Immunotherapy ,
Company ,
Seeking ,
O ,
Advance ,
The ,
Text ,
Generation ,
F ,
Engineered ,
,
Fell ,
Herapeutics ,
Hat ,
Employ ,
Hagocytic ,
Its ,
Head ,
Product ,
Candidate ,
Xpected Pbax Us71902k1051 ,
vimarsana.com © 2020. All Rights Reserved.